Table Graph
   

anti-interleukin-6 - versus control - for COVID-19 severe or critically pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 0.99 [0.72, 1.37]< 115%6 studies (6/-)51.6 %some concernnot evaluable moderatecrucial-
deaths 0.73 [0.63, 0.86]< 119%20 studies (12/8)100.0 %moderatelow moderatecrucial-
deaths (time to event analysis only) 0.82 [0.64, 1.05]< 128%6 studies (3/3)94.5 %moderatenot evaluable moderatecrucial-
clinical deterioration 0.56 [0.26, 1.20]< 10%1 study (1/-)93.1 %NAnot evaluable important-
clinical improvement 1.36 [1.05, 1.76]> 155%4 studies (4/-)99.0 %some concernnot evaluable moderateimportant-
clinical improvement (14-day) 1.86 [1.20, 2.87]> 10%1 study (1/-)99.7 %NAnot evaluable important-
clinical improvement (28-day) 1.19 [0.81, 1.75]> 10%1 study (1/-)81.0 %NAnot evaluable important-
clinical improvement (time to event analysis only) 1.09 [0.87, 1.35]> 10%2 studies (2/-)76.9 %some concernnot evaluable moderateimportant-
death or ventilation 0.96 [0.65, 1.43]< 126%3 studies (3/-)57.8 %some concernnot evaluable moderateimportant-
hospital discharge 0.97 [0.79, 1.20]> 10%1 study (1/-)38.9 %NAnot evaluable important-
mechanical ventilation 1.16 [0.27, 4.99]< 165%2 studies (2/-)42.1 %some concernnot evaluable moderateimportant-
ICU admission 1.04 [0.17, 6.33]< 175%2 studies (2/-)48.5 %some concernnot evaluable moderatenon important-
recovery 0.64 [0.14, 2.92]> 10%1 study (1/-)28.3 %NAnot evaluable non important-

safety endpoints 00

serious adverse events 0.99 [0.77, 1.28]< 116%6 studies (6/-)52.7 %some concernserious moderateimportant-
superinfection 3.27 [1.66, 6.43]< 10%1 study (-/1)0.0 %NAnot evaluable important-
adverse events 1.18 [0.95, 1.48]< 10%5 studies (5/-)7.1 %some concernnot evaluable moderatenon important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.



 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons